Supplementary Figure 7 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors

Genomic characterization of NSCLC harboring oncogenic / likely oncogenic MET TKD mutations in cohort #1 and #2. Genomic characteristics of 44 NSCLC cases harboring oncogenic / likely oncogenic MET TKD mutations from cohort #1: (A) concurrent driver alterations and (B) concurrent MET amplification status (information unavailable for 4 cases). Genomic characteristics of 129 NSCLC cases harboring oncogenic / likely oncogenic MET TKD mutations from cohort #2: (C) concurrent driver alterations and (D) concurrent MET amplification status.